Dupixent®
Dupilumab is a fully human anti-IL-4Rα monoclonal antibody that inhibits both IL-4 and IL-13 signaling. Transformative for type 2 inflammatory diseases.
| Dosage Form | SC Injectable (Prefilled Syringe / Pen) |
| Strength | 200 mg, 300 mg |
| Storage | Store at 2–8°C. May store at room temperature (up to 25°C) for up to 14 days. |
| Category | Immunology |
| Availability | Available for Transfer |
Atopic dermatitis (moderate-to-severe); asthma (eosinophilic/OCS-dependent); chronic rhinosinusitis with nasal polyps; eosinophilic esophagitis; prurigo nodularis; COPD (type 2 inflammation).
Binds to IL-4 receptor alpha subunit, blocking both IL-4 and IL-13 signaling. Inhibits type 2 inflammation by reducing IgE production, eosinophil recruitment, and mucus production.
Each Burrard Pharmaceuticals technology transfer package for Dupilumab includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.